×
About 28,278 results

ALLMedicine™ Psoriasis Center

Research & Reviews  8,521 results

Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Resul...
https://doi.org/10.1111/dth.15166
Dermatologic Therapy; Colombo D, Bianchi L et. al.

Oct 23rd, 2021 - CANOVA study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adul...

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03897088

Oct 21st, 2021 - This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.

Delineating factors behind frequent biologic switching in psoriasis
https://www.mdedge.com/dermatology/article/247687/psoriasis/delineating-factors-behind-frequent-biologic-switching

Oct 20th, 2021 - Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the lo.

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
https://doi.org/10.1007/s40272-021-00476-w 10.1007/s40272-021-00443-5 10.1007/s13555-020-00373-z 10.1016/j.jaad.2019.08.049 10.1177/2475530319897462 10.1007/s12016-018-8702-3 10.1007/s40257-015-0143-7 10.1007/s40265-021-01476-3 10.1007/s40265-016-0602-3 10.1007/s40265-019-01075-3 10.1007/s40265-016-0598-8 10.1111/jdv.17002 10.1016/j.jaad.2021.08.066
Paediatric Drugs; Blair HA

Oct 20th, 2021 - Subcutaneous secukinumab (Cosentyx®) is a recombinant, fully human, immunoglobulin (Ig) G1κ monoclonal antibody targeted against interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab is approved in...

Efficacy of combined fractional carbon dioxide laser and topical tazarotene in nail pso...
https://doi.org/10.1111/jocd.14536
Journal of Cosmetic Dermatology; Essa Abd Elazim N, Mahmoud Abdelsalam A et. al.

Oct 20th, 2021 - Treatment of nail psoriasis is disappointing; due to poor penetrability of topical therapies and variable efficacy of systemic therapies. Fractional carbon dioxide laser (FCL) may enhance penetration of topical therapy for nail psoriasis. To evalu...

see more →

Guidelines  22 results

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 7th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Portuguese recommendations for the treatment of psoriasis with biologic therapy.
https://doi.org/10.1684/ejd.2020.3945
European Journal of Dermatology : EJD; Torres T, Tavares Bello R et. al.

Dec 11th, 2020 - Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients' quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of th...

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471802
Journal of the American Academy of Dermatology; Gelfand JM, Armstrong AW et. al.

Sep 7th, 2020 - To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and...

see more →

Drugs  819 results see all →

Clinicaltrials.gov  283 results

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03897088

Oct 21st, 2021 - This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.

Carpal Tunnel Syndrome in Patients With Psoriatic Arthritis; Ultrasonography and Magnetic Resonance Imaging Findings
https://clinicaltrials.gov/ct2/show/NCT05086042

Oct 20th, 2021 - Carpal tunnel syndrome (CTS) is a type of entrapment neuropathy, caused by compression of the median nerve in the carpal tunnel at the wrist1. It accounts for about 90% of all entrapment neuropathies. But there is no gold standard technique for di...

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are...
https://clinicaltrials.gov/ct2/show/NCT04908475

Oct 15th, 2021 - Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with modera...

Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
https://clinicaltrials.gov/ct2/show/NCT03395340

Oct 15th, 2021 - Background: Chronic graft-versus-host disease (cGVHD) develops in approximately half of individuals who undergo allogeneic hematopoietic cell transplant (HCT) and is the leading cause of non-relapse mortality. There are no skin-targeted therapies ...

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05073315

Oct 15th, 2021 - Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque pso...

see more →

News  1,645 results

Delineating factors behind frequent biologic switching in psoriasis
https://www.mdedge.com/dermatology/article/247687/psoriasis/delineating-factors-behind-frequent-biologic-switching

Oct 20th, 2021 - Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the lo.

PsA Prevention Study With Biologics Contradicts Prior Findings
https://www.medscape.com/viewarticle/960843

Oct 14th, 2021 - A new study has found that patients with psoriasis who were treated with biologics were more likely to develop psoriatic arthritis (PsA) than those treated with phototherapy, oral therapy, or no therapy at all, although the authors cautioned reade...

Treatment-Related Dermatologic AEs in Melanoma Require Careful Management
https://www.onclive.com/view/treatmentrelated-dermatologic-aes-in-melanoma-require-careful-management

Oct 6th, 2021 - Tracey Liebman, MD Optimal management of treatment-related dermatologic adverse events (AEs) in patients with melanoma is essential for proper care, according to Tracey Liebman, MD. For the patients who develop nonspecific rash, pruritus or itch...

Nonsteroidal Topical Found Effective for Psoriasis in 52-Week Study
https://www.medscape.com/viewarticle/960155

Oct 4th, 2021 - Treatment with tapinarof 1%, a nonsteroidal topical cream in clinical development, was associated with durable control of plaque psoriasis in a 52-week phase 3 trial presented as a latebreaker at the European Academy of Dermatology and Venereology...

First-in-Class TYK Inhibitor Shows Durable Effect for Psoriasis
https://www.medscape.com/viewarticle/960105

Oct 1st, 2021 - Deucravacitinib, a novel inhibitor of the JAK kinase tyrosine kinase 2 (TYK2), continues to demonstrate strong efficacy and acceptable safety after 52 weeks of follow-up, according to late-breaking data from two pivotal trials presented at the Eur...

see more →

Patient Education  21 results see all →